Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

1. Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation

Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Signal - Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Dissemination Centre Discover Portal NIHR DC Discover Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Published on 6 February 2018 In people with atrial fibrillation needing anticoagulant (...) treatment, deaths were fewer in those who had direct acting oral anticoagulants compared with warfarin. The picture is less clear for the risk of stroke and complications such as bleeding in the brain or gut. Apixaban had the best efficacy and safety profile and was cost-effective compared with warfarin. This study pooled the data in all trials reporting efficacy, safety and cost of anticoagulant prevention of stroke events in people with atrial fibrillation. Researchers used a technique called network

NIHR Dissemination Centre2019

2. Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits

Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits Signal - Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits Dissemination Centre Discover Portal NIHR DC Discover Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits Published on 27 September 2016 When treating atrial fibrillation, short-term use of rhythm control (...) drugs after catheter ablation reduced the risk of abnormal heart rhythms in the three months after the procedure. They were of no benefit in preventing recurrence of atrial fibrillation in the longer term. Atrial fibrillation is a common abnormal heart rhythm that carries a high risk of stroke. Catheter ablation can be used to destroy the electrical pathways in the heart muscle that cause the abnormal rhythm, but recurrence is common. Several factors could influence the likelihood of abnormal

NIHR Dissemination Centre2019

3. Alternative drug may prevent atrial fibrillation following heart surgery

Alternative drug may prevent atrial fibrillation following heart surgery Signal - Alternative drug may prevent atrial fibrillation following heart surgery Dissemination Centre Discover Portal NIHR DC Discover Alternative drug may prevent atrial fibrillation following heart surgery Published on 12 December 2017 After heart surgery around a third of people have atrial fibrillation, an abnormal heart rhythm, which impedes their recovery and lengthens hospital stay. Colchicine treatment could (...) reduce this complication by about a third. About 11 people would need this treatment to prevent one of them developing atrial fibrillation. Using amiodarone, an alternative drug commonly used in this situation, other research shows that about seven people would be treated to prevent one person suffering fibrillation. Colchicine is a drug licensed for the treatment of gout that combines both anti-inflammatory and heart rate control properties. As an older drug, it might be a cheaper alternative

NIHR Dissemination Centre2019

4. Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation

Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Signal - Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Dissemination Centre Discover Portal NIHR DC Discover Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Published on 18 July 2017 General practice software that generated screen reminders for patients with atrial fibrillation did not increase the proportion taking oral (...) anticoagulants appropriately by six months. This NIHR-funded trial included GPs in 47 surgeries in England and found that at the start only 63% of eligible patients with atrial fibrillation were being prescribed anticoagulants. Six months later the rate had increased to 66% in intervention practices and 64% in those following usual practice, a non-significant difference between the groups. Use of the software was associated with increased diagnosis of transient ischemic attack, which could be due to improved

NIHR Dissemination Centre2019

5. Development and validation of a score to detect paroxysmal atrial fibrillation after stroke

Development and validation of a score to detect paroxysmal atrial fibrillation after stroke 30530796 2019 01 08 1526-632X 92 2 2019 Jan 08 Neurology Neurology Development and validation of a score to detect paroxysmal atrial fibrillation after stroke. e115-e124 10.1212/WNL.0000000000006727 Prolonged monitoring times (72 hours) are recommended to detect paroxysmal atrial fibrillation (pAF) after ischemic stroke but this is not yet clinical practice; therefore, an individual patient selection (...) to be predictive for the detection of pAF within 72 hours of Holter monitoring and included in the final score (Age: 0.76 points/year, Stroke Severity NIHSS ≤5 = 9 points, NIHSS >5 = 21 points; to Find AF [AS5F]). The high-risk group defined by AS5F is characterized by a predicted risk between 5.2% and 40.8% for detection of pAF with a number needed to screen of 3 for the highest observed AS5F points within the study population. Regarding the low number of outcomes before generalization of AS5F, the results

EvidenceUpdates2019

6. Dialysis Modality and Incident Atrial Fibrillation in Older Patients With ESRD

Dialysis Modality and Incident Atrial Fibrillation in Older Patients With ESRD 30449517 2018 12 23 1523-6838 2018 Nov 15 American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Dialysis Modality and Incident Atrial Fibrillation in Older Patients With ESRD. S0272-6386(18)31017-5 10.1053/j.ajkd.2018.09.011 Atrial fibrillation (AF) is common in patients with kidney failure treated by maintenance dialysis. Whether the incidence of AF differs (...) between patients receiving hemodialysis and peritoneal dialysis is uncertain. Retrospective cohort study. Using the US Renal Data System, we identified older patients (≥67 years) with Medicare Parts A and B who initiated dialysis therapy (1996-2011) without a diagnosis of AF during the prior 2 years. Dialysis modality at incident end-stage renal disease (ESRD) and maintained for at least 90 days. Patients were followed up for 36 months or less for a new diagnosis of AF. Time-to-event analysis using

EvidenceUpdates2019

7. Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure: A Meta-analysis of Randomized Controlled Trials.

Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure: A Meta-analysis of Randomized Controlled Trials. Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist and are associated with increased morbidity and mortality risk. Purpose: To compare benefits and harms between catheter ablation and drug therapy in adult patients with AF and HF. Data Sources: ClinicalTrials.gov, PubMed, Web of Science (Clarivate Analytics), EBSCO Information Services, Cochrane (...) Central Register of Controlled Trials, Google Scholar, and various scientific conference sessions from 1 January 2005 to 1 October 2018. Study Selection: Randomized controlled trials (RCTs) published in English that had at least 6 months of follow-up and compared clinical outcomes of catheter ablation versus drug therapy in adults with AF and HF. Data Extraction: 2 investigators independently extracted data and assessed study quality. Data Synthesis: 6 RCTs involving 775 patients met inclusion

Annals of Internal Medicine2018

8. Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation.

Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. Importance: Atrial fibrillation (AF) is the most common arrhythmia affecting 1% of the population. Young individuals with AF have a strong genetic association with the disease, but the mechanisms remain incompletely understood. Objective: To perform large-scale whole-genome sequencing to identify genetic variants related to AF. Design, Setting, and Participants: The National Heart, Lung, and Blood (...) Institute's Trans-Omics for Precision Medicine Program includes longitudinal and cohort studies that underwent high-depth whole-genome sequencing between 2014 and 2017 in 18 526 individuals from the United States, Mexico, Puerto Rico, Costa Rica, Barbados, and Samoa. This case-control study included 2781 patients with early-onset AF from 9 studies and identified 4959 controls of European ancestry from the remaining participants. Results were replicated in the UK Biobank (346 546 participants

JAMA2018

9. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review

Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review 30376678 2018 12 03 2567-689X 118 12 2018 Dec Thrombosis and haemostasis Thromb. Haemost. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. 2171-2187 10.1055/s-0038-1675400 Atrial fibrillation (AF) is a common cardiac arrhythmia that increases the risk of stroke. Medical therapy for decreasing stroke risk (...) involves anticoagulation, which may increase bleeding risk for certain patients. In determining the optimal therapy for stroke prevention for patients with AF, clinicians use tools with various clinical, imaging and patient characteristics to weigh stroke risk against therapy-associated bleeding risk. This article reviews published literature and summarizes available risk stratification tools for stroke and bleeding prediction in patients with AF. We searched for English-language studies in PubMed

EvidenceUpdates2018

10. Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients

Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients 30482761 2018 11 28 2473-9537 2 22 2018 Nov 27 Blood advances Blood Adv Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. 3193-3195 10.1182/bloodadvances.2018027078 Willmann Stefan S Clinical Pharmacometrics, Bayer AG, Wuppertal, Germany. Zhang Liping L Global Clinical Pharmacology

Blood advances2018 Full Text: Link to full Text with Trip Pro

11. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update

Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE In partnership with Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update October 2018Comparative Effectiveness Review Number 214 Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Sanders GD, Lowenstern A, Borre E, Chatterjee R, Goode A, Sharan L, Allen LaPointe NM, Raitz G, Shah B, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al-Khatib S. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update. Comparative Effectiveness Review No. 214. (Prepared

Effective Health Care Program (AHRQ)2018

12. Standardized Library of Atrial Fibrillation Outcome Measures

Standardized Library of Atrial Fibrillation Outcome Measures Research White Paper Standardized Library of Atrial Fibrillation Outcome Measures Research White Paper Standardized Library of Atrial Fibrillation Outcome Measures Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2014-00004-C Prepared by: L&M Policy Research, LLC Washington, DC With partner: OM1, AcademyHealth (...) access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Gliklich RE, Leavy MB, Li F. Standardized Library of Atrial Fibrillation Outcome Measures. Research White Paper. (Prepared by L&M Policy Research, LLC under Contract No. 290-2014-00004-C.) AHRQ Publication No. 18(19)-EHC026-EF. Rockville, MD: Agency for Healthcare Research and Quality; November 2018. Posted final reports are located on the Effective Health Care Program search page. DOI: https://doi.org

Effective Health Care Program (AHRQ)2018

13. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report

Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report Gregory Y. H. Lip, MD; Amitava Banerjee, MD, DPhil; Giuseppe Boriani, MD, PhD; Chern en Chiang, MD, PhD; Ramiz Fargo, MD, FCCP; Ben Freedman, MD, PhD; Deirdre A. Lane, PhD; Christian T. Ruff, MD, MPH; Mintu Turakhia, MD; David Werring, PhD; Sheena Patel, MPH; and Lisa Moores, MD, FCCP BACKGROUND (...) : Theriskofstrokeisheterogeneousacrossdifferentgroupsofpatientswithatrial ?brillation (AF), being dependent on the presence of various stroke risk factors. We provide recommendations for antithrombotic treatment based on net clinical bene?t for patients with AF at varying levels of stroke risk and in a number of common clinical scenarios. METHODS: Systematic literature reviews were conducted to identify relevant articles published from the last formal search perfomed for the Antithrombotic and Thrombolytic Therapy: AmericanCollegeofChestPhysiciansEvidence

American College of Chest Physicians2018

14. Can Multidetector Computed Tomography Rule Out Left Atrial Thrombus in Patients With Atrial Fibrillation? (SRS Diagnosis)

Can Multidetector Computed Tomography Rule Out Left Atrial Thrombus in Patients With Atrial Fibrillation? (SRS Diagnosis) Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements

Annals of Emergency Medicine Systematic Review Snapshots2018

15. Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants?

Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements

Annals of Emergency Medicine Systematic Review Snapshots2018

16. Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery

Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery 30336826 2018 10 19 1558-3597 72 17 2018 Oct 23 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery. 2027-2036 S0735-1097(18)37078-5 10.1016/j.jacc.2018.07.088 The long-term risk of thromboembolism in patients developing new-onset post-operative atrial fibrillation (POAF) following noncardiac surgery (...) is unknown, and data on stroke prophylaxis in this setting are lacking. The purpose of this study was to assess the long-term risk of thromboembolism in patients developing new-onset POAF following noncardiac surgery relative to patients with nonsurgical, nonvalvular atrial fibrillation (NVAF). Using Danish nationwide registries, the authors identified all patients who developed POAF following noncardiac surgery from 1996 to 2015. These were matched by age, sex, heart failure, hypertension, diabetes

EvidenceUpdates2018

17. Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation

Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation 2018 CCS Focused Update of the Guidelines for the Management of Atrial Fibrillation Consulting Fees/ Honoraria Clinical Trials Other Financial Benefit Laurent Macle Abbott Canada, Bayer, BMS Pfizer, Boehringer Ingelheim, Johnson & Johnson, Servier Johnson & Johnson, Servier Atul Verma Bayer, Johnson & Johnson, Medtronic Johnson & Johnson Jason Andrade Bayer, BMS Pfizer, Medtronic, Servier (...) process. Below is a list of all disclosures for the AF panel, regardless of relevance to the 2018 AF Guideline Update. For more information on the CCS Guideline Development process, please visit www.ccs.ca. Page 1 2018 CCS Focused Update of the Guidelines for the Management of Atrial Fibrillation Consulting Fees/ Honoraria Clinical Trials Other Financial Benefit Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content

Canadian Cardiovascular Society2018

18. Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study)

Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study) 30025177 2018 10 25 1553-2712 2018 Jul 19 Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study). 10.1111/acem.13522 We aim (...) to determine the benefit of two different doses magnesium sulfate (MgSO 4 ) compared to placebo in rate control of rapid atrial fibrillation (AF) managed in the emergency department (ED). We undertook a randomized, controlled, double-blind clinical trial in three university hospital EDs between August 2009 and December 2014. Patients > 18 years with rapid AF (>120 beats/min) were enrolled and randomized to 9 g of intravenous MgSO 4 (high-dose group, n = 153), 4.5 g of intravenous MgSO 4 (low-dose group, n

EvidenceUpdates2018

19. Usefulness of the CHA2DS2-VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With Atrial Fibrillation

Usefulness of the CHA2DS2-VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With Atrial Fibrillation 30342698 2018 10 21 1879-1913 2018 Sep 13 The American journal of cardiology Am. J. Cardiol. Usefulness of the CHA 2 DS 2 -VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With Atrial Fibrillation. S0002-9149(18)31761-2 10.1016/j.amjcard.2018.08.056 Sudden cardiac death (SCD), the most devastating (...) manifestation of ventricular arrhythmias (VAs), is the leading cause of mortality in patients with atrial fibrillation (AF). We hypothesized that the CHA 2 DS 2 -VASc score, consisting of age and several clinical risk factors, could be used to estimate the individual risk of SCD/VAs for AF patients. From year 2000 to 2011, 288,181 newly-diagnosed AF patients without antecedent SCD/VAs were identified from "Taiwan National Health Insurance Research Database." During the follow-up of 1,065,751 person-years

EvidenceUpdates2018

20. Periprocedural Outcomes of Direct Oral Anticoagulants vs. Warfarin in Non-Valvular Atrial Fibrillation: A Meta-analysis of Phase III Trials

Periprocedural Outcomes of Direct Oral Anticoagulants vs. Warfarin in Non-Valvular Atrial Fibrillation: A Meta-analysis of Phase III Trials 29794081 2018 10 25 1524-4539 138 14 2018 Oct 02 Circulation Circulation Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. 1402-1411 10.1161/CIRCULATIONAHA.117.031457 Direct oral anticoagulants (DOACs) are surpassing warfarin as the anticoagulant of choice for stroke prevention in nonvalvular (...) atrial fibrillation. DOAC outcomes in elective periprocedural settings have not been well elucidated and remain a source of concern for clinicians. The aim of this meta-analysis was to evaluate the periprocedural safety and efficacy of DOACs versus warfarin in patients with nonvalvular atrial fibrillation. We reviewed the literature for data from phase III randomized controlled trials comparing DOACs with warfarin in the periprocedural period among patients with nonvalvular atrial fibrillation. Substudies from 4

EvidenceUpdates2018